Get started
Author

Dmitrii Iu. Shemetov

Observed names: D. Yu. Shemetov, Dmitrii Shemetov, Шеметов Д.Ю., Шеметов Дмитрий Юрьевич
ORCID: 0009-0009-4370-6218
Observed ORCID: 0009-0009-4370-6218
OpenAlex ID: A5092795565
Efficacy and safety of cabozantinib in metastatic renal cell carcinoma patients: Russian multicenter observational study
2023 · M. I. Volkova, A. S. Kalpinskiy, et al. · Cancer Urology · 3
Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study
2023 · Maria I. Volkova, Alexey S. Kalpinskiy, et al. · Journal of Modern Oncology · 1
PDF
Abstract B036: Prevalence of non-clear cell renal cell carcinoma based on new WHO classification: Results from a multicenter BUCARE Study
2026 · Vladislav Petkau, Dmitrii Shemetov, et al. · Cancer Research
Combination of atezolizumab and bevacizumab in patients with inoperable hepatocellular cancer in real clinical practice
2024 · V. V. Petkau, D. Yu. Shemetov, et al. · Meditsinskiy sovet = Medical Council
Комбинация атезолизумаба и бевацизумаба у больных неоперабельным гепатоцеллюлярным раком в реальной клинической практике
· Петкау Владислав Владимирович, Шеметов Дмитрий Юрьевич, et al. · CyberLeninK (CyberLeninka)
Works count: 6
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type